Kringle Pharma, Inc. (4884) AI Stock Analysis

• Market Cap: ¥2.79B
• Dividend Yield: N/A
• Average Volume (3M): 51.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: -9.77%
• EPS Growth: -13.86%
• Country: JP
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -25.57
• Shares Outstanding: 7,349,200
• 10 Day Avg. Volume: 53,170
• 30 Day Avg. Volume: 51,600
• PEG Ratio: -0.26
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 43.77
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: ¥370.00 ▼(-2.37% Downside)

The score is driven primarily by weak financial performance (volatile and contracting revenue, large losses, and heavy cash burn) despite the benefit of zero debt. Technicals add pressure with a downtrend versus key moving averages and negative MACD. Valuation provides limited support due to negative earnings and no dividend yield data.

Positive Factors

Global Expansion

The establishment of a U.S. subsidiary expands Kringle Pharma's global footprint, potentially accelerating development and commercialization in a key market, enhancing long-term growth prospects.

Regulatory Advantage

The orphan drug designation provides regulatory benefits, including market exclusivity, which can enhance the competitive position and profitability of Kringle Pharma's products.

Debt-Free Balance Sheet

A debt-free balance sheet reduces financial risk, providing Kringle Pharma with greater flexibility to invest in R&D and strategic initiatives without the burden of interest obligations.

Negative Factors

Cash Flow Challenges

Persistent negative cash flow indicates significant cash burn, which may necessitate additional funding and could strain financial resources, impacting long-term sustainability.

Declining Equity

The decline in equity reflects sustained losses, eroding the capital base and potentially limiting the company's ability to invest in growth opportunities without external financing.

Revenue Volatility

Volatile and contracting revenue suggests instability in the business model, which can hinder strategic planning and long-term growth, affecting investor confidence and operational stability.

Kringle Pharma, Inc. Business Overview & Revenue Model

Company Description

Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.

How the Company Makes Money

Kringle Pharma, Inc. generates revenue through the development and commercialization of its proprietary therapeutic products. The company primarily earns money by advancing its drug candidates through clinical trials and subsequently licensing these products to pharmaceutical companies. Revenue streams include milestone payments from partnerships, licensing agreements, and potential royalties from product sales once the therapies reach the market. Strategic collaborations with other biotech and pharma companies also play a significant role in funding its research and development efforts, contributing to its earnings.

Kringle Pharma, Inc. Financial Statement Overview

Summary

Low leverage with zero debt supports the balance sheet, but operating fundamentals are weak: revenue is volatile and recently contracted (~25% in 2025 vs. 2024), losses remain large relative to sales, equity has been eroded by sustained losses, and cash burn is significant with strongly negative operating cash flow in 2024–2025.

Income Statement

Revenue is volatile and has recently contracted (down ~25% in 2025 vs. 2024 after prior swings), while profitability remains deeply negative. Net losses are large relative to sales (net margin ~-13% in 2025 and ~-9% in 2024), indicating the business is still far from operating leverage; gross profit data is also inconsistent year-to-year (including a 0 gross profit reading in 2025), adding uncertainty to the underlying margin picture. The main strength is that revenue continues to exist at a meaningful level for a development-stage biotech, but the scale of ongoing losses is the dominant issue.

Balance Sheet

The balance sheet is conservatively levered with zero debt across the periods shown, which materially reduces financial risk. However, equity has declined notably from prior years (e.g., from ~2.8B in 2022 to ~1.3B in 2025), reflecting sustained losses, and returns on equity are sharply negative (about -70% in 2025). Overall, low leverage is a clear positive, but continuing losses are eroding the capital base.

Cash Flow

Cash generation is weak, with operating cash flow negative in most years and strongly negative in the last two periods (about -756M in 2025 and -661M in 2024), consistent with heavy cash burn. The only bright spot is that 2022 showed modest positive operating and free cash flow, but it was not sustained, and the cash flow profile reverted to sizeable outflows thereafter. This raises ongoing funding risk despite the lack of debt.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	72.40M	72.22M	80.04M	69.25M	391.83M	289.76M
Gross Profit	72.40M	72.22M	80.04M	69.25M	303.42M	218.16M
EBITDA	-976.02M	-914.76M	-817.88M	-888.76M	-426.17M	-357.88M
Net Income	-977.06M	-916.25M	-756.45M	-854.15M	-331.83M	-301.17M
Balance Sheet
Total Assets	2.11B	2.08B	2.76B	2.62B	3.21B	2.64B
Cash, Cash Equivalents and Short-Term Investments	1.63B	1.62B	2.31B	2.14B	2.76B	2.14B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	719.58M	770.11M	648.92M	596.95M	419.50M	129.48M
Stockholders Equity	1.39B	1.31B	2.11B	2.02B	2.79B	2.51B
Cash Flow
Free Cash Flow	0.00	0.00	-661.17M	-689.10M	15.80M	-560.92M
Operating Cash Flow	0.00	-755.78M	-661.17M	-689.10M	15.80M	-560.92M
Investing Cash Flow	0.00	-154.01M	-121.36M	-120.88M	-254.38M	0.00
Financing Cash Flow	0.00	84.14M	838.23M	69.16M	603.11M	595.90M

Kringle Pharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 379.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Negative. The current price of 379 is below the 20-day moving average (MA) of 398.30, below the 50-day MA of 393.32, and below the 200-day MA of 573.92, indicating a bearish trend. The MACD of -4.30 indicates Positive momentum. The RSI at 38.30 is Neutral, neither overbought nor oversold. The STOCH value of 9.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4884.

Kringle Pharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4594	53 Neutral	¥9.36B	-6.15	―	―	1221.43%	30.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4588	50 Neutral	¥49.97B	-20.76	―	―	-9.04%	13.09%
3750	45 Neutral	¥7.79B	-4.23	―	―	-93.79%	-1332.86%
4884	42 Neutral	¥2.79B	-2.84	―	―	-9.77%	-13.86%
4564	42 Neutral	¥7.53B	-6.95	-63.25%	―	99.87%	40.60%
4598	39 Underperform	¥2.80B	-1.42	―	―	―	25.25%

Kringle Pharma, Inc. Corporate Events

Kringle Pharma Reports Increased Losses and Decline in Financial Position for FY 2025

Kringle Pharma, Inc. reported its financial results for the fiscal year ending September 30, 2025, showing a decline in net sales and increased losses compared to the previous year. The company’s financial position weakened with reduced total assets and net assets, impacting its equity ratio and cash flows, which may affect its operational strategies and stakeholder confidence.

Kringle Pharma Expands Global Reach with New U.S. Subsidiary

Kringle Pharma, Inc. has announced the establishment of a new subsidiary, Kringle Pharma USA, Inc., to enhance its global footprint and expedite the development of its acute spinal cord injury program in the U.S. market. The subsidiary will be led by Matt Vogelhuber, a seasoned professional in the life sciences industry, and aims to leverage the recent orphan drug designation by the U.S. FDA for Oremepermin alfa to advance clinical development efforts. This strategic move underscores Kringle Pharma’s commitment to innovation and its mission to improve healthcare through HGF-based therapies.